Ocugen, Inc. OCGN
0.77 USD +0.04 (+4.79%)
Regular-session close
0.77 +0.01 +0.87%
After hours · Nov 20, 7:54 PM ET
0.71 Day range 0.8198
0.703 52-week range 2.48
- YTD
- -43.12%
- 1 year
- -30.82%
News
marketbeat.com Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy Ocugen NASDAQ: OCGN expects pivotal data for its lead experimental gene therapy for retinitis pigmentosa in the first quarter of 2027, a milestone that could set up a regulatory filing later that…
globenewswire.com Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and…
zacks.com Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises OCGN's Q3 revenues beat estimates. Shares surge 17.4%.
seekingalpha.com Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript Ocugen, Inc. ( OCGN ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Chris Clark - VP of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Rita…
marketbeat.com Ocugen Q3 Earnings Call Highlights Ocugen NASDAQ: OCGN said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European…benzinga.com UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period…
zacks.com Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates Ocugen (OCGN) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.07 per share a year ago.
benzinga.com Ocugen Q3 2026 Earnings Call Transcript Ocugen (NASDAQ:OCGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…benzinga.com Ocugen Q3 EPS $(0.01) Beats $(0.06) Estimate, Sales $1.951M Beat $1.098M Estimate Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 85.71 percent increase over losses of $(0.07) per…
globenewswire.com Ocugen Provides Business Update with Third Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas Executed agreement with local partner Global Alliance for…
globenewswire.com Ocugen to Participate in Upcoming November Investor and Industry Conferences MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
globenewswire.com Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a…
globenewswire.com Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
prnewswire.com Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
newsfilecorp.com Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the…
globenewswire.com Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to…
globenewswire.com Ocugen to Participate in Upcoming Scientific Conferences MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
globenewswire.com Ocugen to Participate in Upcoming October Investor and Industry Conferences MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…
globenewswire.com Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
marketbeat.com Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive…
seekingalpha.com Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal…
zacks.com OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
globenewswire.com Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…
